Updates of Radioiodine Treatment for Graves' Disease
10.11106/ijt.2019.12.2.85
- Author:
Shin Young JEONG
1
Author Information
1. Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. syjeong@knu.ac.kr
- Publication Type:Review
- Keywords:
Radioactive iodine;
Graves' disease;
Thyroid;
Hyperthyroidism
- MeSH:
Graves Disease;
Hyperthyroidism;
Hypothyroidism;
Incidence;
Korea;
Prospective Studies;
Sodium Iodide;
Thyroid Gland
- From:International Journal of Thyroidology
2019;12(2):85-90
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Radioiodine (RAI) has been used for the treatment of hyperthyroidism and is usually administered orally as sodium iodide (I-131) in solution or a capsule. However, this results in RAI being rapidly incorporated into the thyroid cells, and extensive local tissue damage occurring via beta emissions of I-131. The incidence rate of hypothyroidism is 5–50% at the first year after RAI therapy and is positively associated with the dosage of RAI. RAI has been used since 1960 in Korea; however, there have been few well-designed prospective trials, leaving many questions about indications, optimal dose, efficacy, and side-effects. This review summarizes the latest research pertaining to clinical questions about indications, optimal dose, efficacy, and side-effects.
